





Acuitas Therapeutics Inc.

April 21st, 2026



Who We Are



OUR TECHNOLOGY

Lipid nanoparticle (LNP) are tiny spheres incorporating our proprietary ionizable lipids.

About 1/300th of the width of a human hair, **LNP encapsulates nucleic acids** and delivers it into cells.



WHO WE WORK WITH

- Cutting edge **pharmaceutical & biotechnology** companies
- Leading **academics in universities & institutes**
- **Foundations & NGOs**



HOW WE WORK

We exclusively work in collaboration with partners and are **focused on supporting our partners to bring their drug products to patients.**

Global leader in lipid nanoparticle (LNP) technology



First Approved **RNA interference-based Medicine**

onpattro
(patisiran) lipid complex injection
10 mg/5 mL

Anylam




First Approved **mRNA Vaccine**

COMIRNATY
(COVID-19 Vaccine, mRNA)

Pfizer **BIONTECH**



First **personalized CRISPR gene editing therapy**



CH Children's Hospital
of Philadelphia




A Trusted Partner for Clinical Development

33

Clinical trials enabled by our LNP in the last 3 years

of Products in Clinic Currently



18 in Phase 1



4 in Phase 2



2 in Phase 3

Our Partners in Clinical Development*



alltrna



BIONTECH



ukko

*: Select partners who have publicly disclosed Acuitas' involvement are listed here.

Therapeutic Areas Enabled by Acuitas LNP Technology

Gene Modulation

Expression of an **epigenetic editor** to modify gene expression **without changing the genetic code**.

Antibody & Therapeutic Protein Delivery

Expression of **proteins including prophylactic or therapeutic antibodies** to treat current and emerging diseases.

Gene Editing

Expression of a **genome editing** protein to modify gene expression.

Vaccines

Expression of viral or bacterial proteins to generate a protective **immune response**.


Expression of **tumour antigens** (including personalized cancer vaccines).

In Vivo CAR-T


Expression of a Chimeric Antigen Receptor for **in vivo production of CAR-T cells** to treat cancer and autoimmune disease.



Our Discovery Engine




Next Generation IM Lipids for Vaccine Applications



LEGEND cGMP ready + in clinic

In vivo CAR T, Enabled by Targeted LNP (tLNP)

tLNP enables **cell-specific** delivery



tLNP with *DARPin*
(*Athebody*[™])

tLNP unlock *in vivo* applications in **autoimmune disease and oncology**



Autoimmune indications with **inappropriate immune response**



Oncology indications **to engage immune response**

Proof-of-Concept in Non-Human Primates

CREATE CD20 CAR Product Design

T cell-targeting binder

- CD8-specific DARPin (~15kDa) (Athebody™)

mRNA

- Engineered linear mRNA encoding CD20-BBζ CAR

Acuitas LNP Formulation

- Optimized for T cell targeting
- Lipid clinically validated



NHP Study Design


Study	Dose	Schedule
Study 1	0.25 mg/kg	D0, D3, D6

Observations


- Circulating B cell depletion
- Lymphoid tissue and bone marrow-resident B cell depletion
- Safety; well tolerated

Profound Depletion: Circulating & Tissue B Cells



Complete Blood Depletion



Complete Lymphoid Depletion



Confirmed by IHC




Spleen IHC

Best-in-Class Multivalent & Cancer Vaccine potency

MULTIVALENT VACCINES



Next Generation vaccine LNP show equivalent activity at **5-fold lower dose vs. ALC-315™**.



□ Monovalent LNP ▨ Bivalent LNP

CANCER VACCINES

Acuitas LNP demonstrate **increased levels & activity** of antigen-specific CD8 T cells vs. Clinical Competitor (SM-102).



■ Acuitas LNP ■ Clinical Competitor

Simplified Manufacture via Pre-Formed Vesicles (PFV)

Conventional Manufacture



Pre-Formed Vesicles Opportunity

Enables kit format (2 vials)
where mRNA is loaded into
empty LNP at point-of-care



mRNA



Empty LNP



mRNA-LNP



Bringing Canadian RNA-LNP Expertise to the World

Acuitas Acquired a Majority Stake in RNA T&T (January 2026)

*Global
leader in LNP
delivery*



*World-class RNA
optimization and
manufacturing
know-how*

**Working together to accelerate development
timelines and de-risk clinical programs**

The Acuitas Advantage

1 Best-in-class and First-in-class



2 Accelerated Clinical Entry



3 Unparalleled Scientific Leadership & Experience



**Let's
Connect**

bd@acuitastx.com
<https://acuitastx.com/>